Clinical Trial Update: Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab. [Phase 3]

View source ↗

Summary

Phase 3 head-to-head trial evaluating efficacy and safety of benralizumab versus mepolizumab in eosinophilic granulomatosis with polyangiitis; results were post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Eosinophilic Granulomatosis with Polyangiitis

Drugs mentioned

• Benralizumab (Fasenra) (benralizumab)
• Mepolizumab (Nucala) (mepolizumab)

Snippet

Sponsor: AstraZeneca | Conditions: Eosinophilic Granulomatous Vasculitis | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-01-14